Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
NSC Norfolk Southern Corp
WM Waste Management Inc
ITOS Iteos Therapeutics Inc
CCLD CareCloud Inc
JEF Jefferies Financial Group Inc
RSASF Resaas Services Inc
VRNT Verint Systems Inc
TRHC Tabula Rasa HealthCare Inc
ILMN Illumina Inc

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Day's Change
-12.46 (-1.60%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 550,709 shares is on pace to be lower than REGN's 10-day average volume of 724,147 shares.


AMD sits on a 'key ingredient for market share gains,' analyst says in upgrade

9:33 am ET November 14, 2022 (MarketWatch)

By Emily Bary

Baird analyst says AMD's new server chips reinforce its 'performance leadership for years to come'

Shares of Advanced Micro Devices Inc. were looking to extend their recent rally Monday as one analyst weighed in with an upbeat view of the company's recently debuted data-center chips.

Baird's Tristan Gerra upgraded AMD's (AMD) stock to outperform from neutral Monday, writing that the introduction of the company's new Epyc server processors, dubbed Genoa, improve the company's competitive positioning and seem to be generating a strong reception among data-center customers.

See more: AMD launches 18 models of new Epyc data-center chip

"Genoa's very significant performance step up should translate into an acceleration in market share gains for AMD in 2023 in our view, along with significantly higher pricing and a higher gross margin profile, reinforcing AMD's Epyc performance leadership for years to come before Intel could catch up even assuming on-time execution for Intel 3," Gerra wrote in his note to clients.

AMD shares were up more than 3% in premarket trading Monday. They rallied 14.3% in Thursday's session and gained 5.7% in Friday trading.

Gerra added that AMD "is solidifying its position with a clearly defined, performance-leading and delivery-proven product roadmap to OEMs [original-equipment manufacturers] for the next several years, representing a critical key ingredient for market share gains." This backdrop could make Intel Corp.'s (INTC) Sapphire Rapids "a stale product even as it ramps in 2023," he continued.

AMD completed its acquisition of fellow chipmaker Xilinx in February. Gerra also sees encouraging traction for Xilinx products, writing of "continued supply constraints and strong, above-seasonal demand" and visibility that stretches into the first half of 2023.

Gerra upped his price target on AMD shares to $100 from $65.

UBS analyst Timothy Arcuri also turned bullish on AMD's stock, citing the potential for improvement in PC trends.

"We see AMD as poised for rebound in the near-term especially on the back of the peak PC digestion year" in 2022, he wrote, as he lifted his rating on AMD shares to buy from neutral and raised his price target to $95 from $75.

Arcuri added that his analysis of past semiconductor cycles by subsector found that "AMD has been typically one of the best outperformers off the bottom of a cycle."

The stock has lost about half its value so far this year, while the S&P 500 has declined 16%.

-Emily Bary


(END) Dow Jones Newswires

November 14, 2022 09:33 ET (14:33 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.